Covenant Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-387
| Closed | -$245K | – | 167 |
|
|
2025
Q1 | $245K | Sell |
387
-511
| -57% | -$351K | 0.05% | 145 |
|
|
2024
Q4 | $640K | Sell |
898
-5,445
| -86% | -$4.57M | 0.1% | 111 |
|
|
2024
Q3 | $6.67M | Sell |
6,343
-7
| -0.1% | -$7.79K | 1.05% | 27 |
|
|
2024
Q2 | $6.67M | Sell |
6,350
-5
| -0.1% | -$4.85K | 1.06% | 24 |
|
|
2024
Q1 | $6.12M | Sell |
6,355
-11
| -0.2% | -$10.5K | 1% | 25 |
|
|
2023
Q4 | $5.59M | Buy |
6,366
+222
| +4% | +$183K | 1% | 23 |
|
|
2023
Q3 | $5.06M | Buy |
6,144
+1,940
| +46% | +$1.52M | 1.33% | 18 |
|
|
2023
Q2 | $3.02M | Buy |
4,204
+3,804
| +951% | +$2.93M | 0.77% | 48 |
|
|
2023
Q1 | $329K | Hold |
400
| – | – | 0.08% | 136 |
|
|
2022
Q4 | $289K | Sell |
400
-28,660
| -99% | -$21.1M | 0.07% | 147 |
|
|
2022
Q3 | $3.93M | Buy |
29,060
+20,572
| +242% | +$12.9M | 1.12% | 23 |
|
|
2022
Q2 | $5.02M | Sell |
8,488
-3,114
| -27% | -$2.02M | 1.59% | 11 |
|
|
2022
Q1 | $8.1M | Sell |
11,602
-364
| -3% | -$230K | 2.19% | 10 |
|
|
2021
Q4 | $7.56M | Sell |
11,966
-13
| -0.1% | -$7.99K | 2.01% | 9 |
|
|
2021
Q3 | $7.25M | Buy |
11,979
+208
| +2% | +$129K | 2.15% | 10 |
|
|
2021
Q2 | $6.58M | Buy |
11,771
+10,800
| +1,112% | +$5.47M | 1.96% | 11 |
|
|
2021
Q1 | $459K | Hold |
971
| – | – | 0.14% | 111 |
|
|
2020
Q4 | $469K | Hold |
971
| – | – | 0.15% | 103 |
|
|
2020
Q3 | $544K | Hold |
971
| – | – | 0.17% | 93 |
|
|
2020
Q2 | $606K | Sell |
971
-335
| -26% | -$190K | 0.13% | 90 |
|
|
2020
Q1 | $638K | Hold |
1,306
| – | – | 0.19% | 88 |
|
|
2019
Q4 | $490K | Sell |
1,306
-26
| -2% | -$8.75K | 0.21% | 99 |
|
|
2019
Q3 | $369K | Sell |
1,332
-234
| -15% | -$69.2K | 0.19% | 114 |
|
|
2019
Q2 | $490K | Sell |
1,566
-122
| -7% | -$40.6K | 0.25% | 97 |
|
|
2019
Q1 | $693K | Buy |
1,688
+792
| +88% | +$326K | 0.36% | 78 |
|
|
2018
Q4 | $362K | Hold |
896
| – | – | 0.18% | 110 |
|
|
2018
Q3 | $362K | Sell |
896
-22
| -2% | -$8.37K | 0.18% | 110 |
|
|
2018
Q2 | $317K | Sell |
918
-50
| -5% | -$15.6K | 0.17% | 114 |
|
|
2018
Q1 | $333K | Sell |
968
-2,992
| -76% | -$1.04M | 0.19% | 109 |
|
|
2017
Q4 | $1.49M | Sell |
3,960
-75
| -2% | -$30.4K | 0.87% | 44 |
|
|
2017
Q3 | $1.8M | Buy |
4,035
+2
| +0% | +$952 | 1.1% | 33 |
|
|
2017
Q2 | $1.98M | Sell |
4,033
-23
| -0.6% | -$10.1K | 1.27% | 24 |
|
|
2017
Q1 | $1.57M | Sell |
4,056
-1,296
| -24% | -$480K | 1.06% | 34 |
|
|
2016
Q4 | $1.97M | Buy |
+5,352
| New | +$2.04M | 1.32% | 26 |
|
Other funds holding REGN
Covenant Asset Management's REGN Position: Q2 2025 in Review
Covenant Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 387 shares — an estimated $245K sold.
Covenant Asset Management first reported a position in REGN in Q4 2016 and held it in 34 quarters. The position peaked at $8.1M in Q1 2022. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.
- Covenant Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Covenant Asset Management sold 387 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $245K.
- Covenant Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 34 quarters.
- Covenant Asset Management's Regeneron Pharmaceuticals position peaked at $8.1M in Q1 2022.
- 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.
Based on Covenant Asset Management's 13F filing for Q2 2025, filed 17 Jul 2025.